Form 8-K

8-K — Akari Therapeutics Plc

Accession: 0001493152-26-037736

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0001541157

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001541157

2026-08-13

0001541157

AKTX:AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember

2026-08-13

0001541157

AKTX:OrdinarySharesParValue0.000000005PerShareMember

2026-08-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 13, 2026

Akari

Therapeutics, Plc

(Exact

Name of Registrant as Specified in Charter)

England

and Wales

001-36288

98-1034922

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

401

East Jackson Street, Suite 3300

Tampa,

FL 33602

(Address,

including zip code, of Principal Executive Offices)

Registrant’s

telephone number, including area code: (929) 274-7510

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class:

Trading

Symbol(s)

Name

of each

exchange

on which registered

American

Depositary Shares, each representing 80,000 Ordinary Shares

AKTX

The

Nasdaq Capital Market

Ordinary

Shares, par value $0.000000005 per share*

*Trading,

but only in connection with the American Depositary Shares.

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02. Results of Operations and Financial Condition.

August 13, 2026, Akari Therapeutics, Plc. (the “Company”) issued a press release announcing its financial results

for the first half of the year ending December 31, 2026 and certain other information. A copy of the press release is being furnished

as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The

information furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the

Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall

it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission

under the Exchange Act or the Securities Act of 1933, whether made before or after the date hereof, regardless of any general

incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by

law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release, dated August 13, 2026, of Akari Therapeutics, Plc.

104

The

cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Akari

Therapeutics, Plc

Date:

August 13, 2026

By:

/s/

Kameel Farag

Kameel

Farag

Interim

Chief Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Akari

Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration

for Its ADC Payload Platform

AKTX-101

advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027

Compelling

ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models

Strategic

research collaboration with Whitehawk Therapeutics expands potential application of Akari’s PH1 platform into dual-payload ADCs

Balance

sheet strengthened by approximately $8.6 million of financing during the quarter, led by long-term strategic investors

TAMPA,

FL and LONDON – August 13, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing

antibody drug conjugates (ADCs) with a novel payload targeting RNA splicing, reported financial results for the second quarter ending

June 30, 2026 and provided an update on the continued advancement of its lead ADC candidate, AKTX-101, towards Phase 1 clinical trials.

“Akari

entered the second half of 2026 with increasing momentum across the business and a clear focus on advancing AKTX-101 towards the clinic,”

said Abizer Gaslightwala, Chief Executive Officer of Akari Therapeutics. “We are executing the IND-enabling work required to support

our planned Phase 1 trial in mid-2027, while continuing to generate data that strengthen the scientific rationale for AKTX-101 and further

differentiate our novel PH1 spliceosome-modulating payload.”

Mr.

Gaslightwala continued, “The compelling data presented at ASCO demonstrated synergistic anti-tumor activity when our PH1 payload

was combined with an approved KRAS inhibitor in KRAS-mutated pancreatic cancer models, adding to a growing body of preclinical evidence

supporting PH1’s differentiated mechanism and potential utility across difficult-to-treat cancers. At the same time, our collaboration

with Whitehawk expands the opportunity for PH1 into dual-payload ADCs and provides another avenue to explore the potential advantages

of combining PH1’s unique mechanism with established ADC payload technologies. Importantly, receipt of approximately $8 million

of financing during the quarter, led by long-term strategic investors, strengthened our balance sheet and enhances our ability to continue

executing against these development priorities.”

Second

Quarter 2026 Highlights

● Strengthened

the balance sheet through private placement with $5.5 million in gross proceeds, and warrant

exercises worth $3.1 million in gross proceeds for a total of approximately $8.6 million

in gross proceeds from financing in the quarter, resulting in approximately $8.0 million

of net proceeds to the Company.

● Continued

advancing AKTX-101 through IND-enabling activities by progressing manufacturing and development

work to enable the Phase 1 clinical trial. The Company remains focused on initiating AKTX-101

for clinical development in mid-2027.

● Expanded

the Company’s strategic position in novel ADC payloads through a research collaboration

on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari’s proprietary PH1

spliceosome modulating payload platform in combination with Whitehawk’s topoisomerase

I payload platform. The collaboration is designed to investigate the potential of combining

complementary ADC payload technologies to synergize and enhance anti-tumor activity. This

collaboration further demonstrates the unique potential of the PH1 payload and continued

strong interest in ADC payload innovation across biotech/pharma.

● Presented

breakthrough preclinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual

Meeting demonstrating synergistic anti-tumor activity of the Company’s PH1 spliceosome

modulating payload combined with an approved KRAS inhibitor in KRAS-mutated pancreatic cancer

models. These data support the potential of using ADCs with the PH1 payload as a way to attack

KRAS mutant tumors, still one of the greatest unmet needs.

● Expanded

the Company’s intellectual property portfolio through newly issued international patents

for its proprietary PH1 spliceosome modulating payload technology, further strengthening

long-term protection of the platform and supporting future ADC pipeline expansion.

Second

Quarter 2026 Financial Results

Research

and development expenses were $2.1 million for the second quarter of 2026, compared with $0.7 million for the second quarter of 2025.

The increase primarily reflects expanded development and manufacturing activities supporting the advancement of AKTX-101 through critical

IND enabling activities.

General

and administrative expenses were $2.5 million for the second quarter of 2026, comparable with $2.5 million for the same period in 2025.

Net

loss for the second quarter of 2026 was $4.8 million, compared with $1.9 million for the second quarter of 2025.

Cash totaled $7.7 million as of June 30, 2026, compared with $5.2 million as of December 31, 2025.

About

Akari Therapeutics

Akari

Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1,

which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and

optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the

Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal

off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload

that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical

animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity.

In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional

payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival

as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against

cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies

for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting

CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple

solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct

to enable differentiated tumor cell killing and immune activation.

For

more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary

Note Regarding Forward-Looking Statements

This

press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,

as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties

relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking

statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,”

“anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

“potential,” “continue,” “future,” “opportunity” “will likely result,” “target,”

variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements,

although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but

are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment

of cancer and the timing of a filing of an IND and commencement of a Phase 1 clinical trial. These statements are based on the Company’s

current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties,

both general and specific. A number of important factors, including those described in this communication, could cause actual results

to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause

these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential

impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance,

indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion

and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency

exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product

candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the

supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs;

the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or

its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company,

and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical

trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of

the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s

ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered

representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information

about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s

filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby

disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor

Relations Contact

JTC

Team, LLC

Jenene

Thomas

908-824-0775

AKTX@jtcir.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (6015 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 20

v3.26.1

Cover

Aug. 13, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-36288

Entity Registrant Name

Akari

Therapeutics, Plc

Entity Central Index Key

0001541157

Entity Tax Identification Number

98-1034922

Entity Incorporation, State or Country Code

Entity Address, Address Line One

401

East Jackson Street

Entity Address, Address Line Two

Suite 3300

Entity Address, City or Town

Tampa

Entity Address, State or Province

Entity Address, Postal Zip Code

33602

City Area Code

(929)

Local Phone Number

274-7510

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

American Depositary Shares, each representing 80,000 Ordinary Shares

Title of 12(b) Security

American

Depositary Shares, each representing 80,000 Ordinary Shares

Trading Symbol

AKTX

Security Exchange Name

NASDAQ

Ordinary Shares, par value $0.000000005 per share*

Title of 12(b) Security

Ordinary

Shares, par value $0.000000005 per share*

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=AKTX_AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=AKTX_OrdinarySharesParValue0.000000005PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: